NewsRoom Articles - BioMedWire (BMW)

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned…

MondayDec 01, 2025 10:00 am

Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation

For a long time, the scientific community has known that anything that causes harm to the body usually also harms our brains. Conditions like insulin resistance, obesity and high blood pressure strain the body’s metabolic and vascular systems. With time, this stress accelerates cognitive decline and amplifies Alzheimer’s risk. Now, a new study conducted by a team at Arizona State University (ASU) together with collaborators elsewhere has shown that the harmful effects often start much earlier than had initially been thought. They observed that obese young adults exhibited a pattern of subtle changes suggesting early brain damage. These same patterns…

TuesdayNov 25, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances

Philipson will serve as a strategic advisor to Soligenix, contributing extensive expertise in U.S. economic policy, healthcare regulation and corporate strategy. The significance of this appointment lies in the convergence of science, healthcare regulation and policy economics. The addition of Philipson complements the company’s mission to develop and commercialize products to treat rare diseases where there is an unmet medical need. Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and healthcare innovation. The company,…

TuesdayNov 25, 2025 10:00 am

Common Drug for Blood Pressure Could Slow Glioblastoma

Researchers studying how a common drug, hydralazine, for blood pressure and preeclampsia works at the cellular level have identified the specific mechanism through which it works and their discovery has revealed that the medication that has been around for more than half a century could find new application as a way to slow down how aggressively glioblastoma grows. Despite how long this drug has been in use, it wasn’t clear how exactly it attained the effects it has upon blood pressure. This isn’t unique to hydralazine, as only 10-20% of all existing medications have known mechanisms of action. In a…

MondayNov 24, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

This milestone is significant because regulatory pathways for orphan diseases such as CTCL often hinge not only on efficacy, but on establishing a favorable safety profile. Soligenix’s announcement arrives amid mounting interest in HyBryte[TM] as a novel skin-directed therapy. For biotechnology companies working in rare diseases, reaching a safety milestone means one major hurdle is cleared and focus can shift more explicitly to efficacy and regulatory strategy. In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM)…

MondayNov 24, 2025 9:00 am

Biotech Valuations Rise as New Clinical Platforms Show Progress

BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (“GAAP”) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (“JV”) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic…

FridayNov 21, 2025 10:00 am

What Patients Need to Know About Exercising During Cancer Treatment

It may sound strange to speak of exercising and cancer treatment in the same breath, but experts and numerous studies have documented the immense value that patients can attain by integrating exercise into their schedule during the duration that they are receiving treatment for cancer. We address some of the queries that cancer patients may have about exercising during their treatment. First off, ASCO (American Society of Clinical Oncology) assembled experts that analyzed at least 100 clinical trials that explored any possible links between cancer treatment and exercise. These experts then published a report of their exercise recommendations back in…

ThursdayNov 20, 2025 10:00 am

Senator Sanders Suggests Six Other Ways to Address Health Crisis

On Tuesday, Senator Bernie Sanders authored a letter that he sent to Democrats in both chambers of Congress urging them to band together and support the Affordable Care Act. He wrote that a lot more can be done to improve healthcare in the country and made six suggestions that can help in attaining this objective. He appeals for an extension to the ACA tax credits designed to lower the cost of health insurance for people who aren’t eligible for Medicare yet they don’t have sufficient employer-provided medical cover. These tax credits were at the heart of the recently-ended government shutdown,…

ThursdayNov 20, 2025 9:00 am

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (“GAAP”) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (“JV”) entity GMP Bio, driven by a new independent valuation indicating a potential step-up in asset value. This key shift strengthens Oncotelic Therapeutics position…

TuesdayNov 18, 2025 10:00 am

Parent Explains Why it is Wrong to Say Vaccines Cause Autism

For a while, the media has been filled with claims that vaccines cause autism. These claims have been amplified by public figures like the U.S. Secretary of Health & Human Services, R. F. Kennedy Jr., as well as other public health leaders. Now a parent, Greg Scaduto, whose child is autistic, has come out to explain why such thinking is misguided and does more harm than good. He explains that these false narratives are founded in a failure to understand the difference between correlation and causation. He says many people quickly, and falsely, jump to the conclusion that when two…